Lördag 23 November | 01:36:55 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-10-30 07:30 Kvartalsrapport 2025-Q3
2025-07-10 07:30 Kvartalsrapport 2025-Q2
2025-05-22 - Årsstämma
2025-05-03 07:30 Kvartalsrapport 2025-Q1
2025-02-13 07:30 Bokslutskommuniké 2024
2024-12-06 - Extra Bolagsstämma 2025
2024-11-05 - Kvartalsrapport 2024-Q3
2024-07-11 - Kvartalsrapport 2024-Q2
2024-06-28 - Årsstämma
2024-06-12 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2024-05-31 - Kvartalsrapport 2024-Q1
2024-02-27 - Bokslutskommuniké 2023
2023-11-02 - Kvartalsrapport 2023-Q3
2023-07-13 - Kvartalsrapport 2023-Q2
2023-07-03 - Extra Bolagsstämma 2023
2023-06-13 - Årsstämma
2023-05-24 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2023-05-04 - Kvartalsrapport 2023-Q1
2023-02-16 - Bokslutskommuniké 2022
2022-11-03 - Kvartalsrapport 2022-Q3
2022-07-14 - Kvartalsrapport 2022-Q2
2022-05-25 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2022-05-24 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-04 - Kvartalsrapport 2021-Q3
2021-07-15 - Kvartalsrapport 2021-Q2
2021-05-26 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2021-05-25 - Årsstämma
2021-05-06 - Kvartalsrapport 2021-Q1
2021-02-18 - Bokslutskommuniké 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-07-16 - Kvartalsrapport 2020-Q2
2020-05-27 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2020-05-26 - Årsstämma
2020-05-07 - Kvartalsrapport 2020-Q1
2020-02-13 - Bokslutskommuniké 2019
2019-11-07 - Kvartalsrapport 2019-Q3
2019-07-18 - Kvartalsrapport 2019-Q2
2019-05-23 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2019-05-22 - Årsstämma
2019-05-03 - Kvartalsrapport 2019-Q1
2019-02-14 - Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Q-Linea är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av instrument och förbrukningsartiklar. Produkterna används huvudsakligen vid behandling av infektionssjukdomar och blodförgiftning, och innefattar diagnostik- och analysverktyg, samt övrig grundläggande provhantering. Tekniken baseras på den så kallade ID- samt AST tekniken. Bolaget grundades 2008 och har huvudkontoret i Uppsala.
2024-09-27 12:10:00

Q-linea AB (publ) (OMX: QLINEA) today announces that the company is expanding into the Middle East through an exclusive agreement with AMICO Group

AMICO Group was founded by Akef El Maghraby M.D. & Mehran Hazarian in 1984. The company employs 1,300+ people with direct operations in 12 countries in the Middle East and North Africa, operating from 22 offices. The exclusive distribution agreement with Q-linea covers the GCC countries, including the United Arab Emirates, Saudi Arabia, Kuwait, Qatar, Bahrain and Oman.

Antimicrobial resistance (AMR) has significantly increased in the region over the past decade. The board members of the Gulf Cooperation Council Center for Infection Control (GCC-IC) developed a draft strategic plan for combating AMR in 2014. The final version was approved in 2016 and each GCC country moved on to develop and implement their respective plans.

Stuart Gander, CEO of Q-linea, said “One of the pillars of the action plans is to optimize use of antibiotics. Potential strategies include rapid diagnostics and the ability to optimize antibiotic dose, both of which the ASTar® System provides. The GCC countries represent a significant opportunity for growth in service to sepsis patients. We are confident that our partnership with AMICO Group will provide outstanding service and support to ASTar customers.”

Sherif Harydi, Business Development Director at AMICO Group, said ” We’re thrilled to announce that AMICO Group is making its mark combating sepsis and fighting AMR in the Middle East by partnering with Q-linea. This exclusive agreement will enable us to distribute the cutting-edge ASTar® System in the GCC countries, including the UAE, Saudi Arabia, Kuwait, Qatar, Bahrain, and Oman. Join us as we embark on this important journey to provide exceptional healthcare across the Middle East!”.